Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Total Current Liabilities: 2021-2025

Historic Total Current Liabilities for InMed Pharmaceuticals (INM) over the last 4 years, with Sep 2025 value amounting to $1.6 million.

  • InMed Pharmaceuticals' Total Current Liabilities rose 8.29% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 8.29%. This contributed to the annual value of $1.8 million for FY2025, which is 6.70% down from last year.
  • InMed Pharmaceuticals' Total Current Liabilities amounted to $1.6 million in Q3 2025, which was down 15.48% from $1.8 million recorded in Q2 2025.
  • In the past 5 years, InMed Pharmaceuticals' Total Current Liabilities registered a high of $4.6 million during Q4 2021, and its lowest value of $1.3 million during Q3 2023.
  • Moreover, its 3-year median value for Total Current Liabilities was $1.8 million (2024), whereas its average is $1.8 million.
  • In the last 5 years, InMed Pharmaceuticals' Total Current Liabilities soared by 70.32% in 2022 and then tumbled by 59.19% in 2023.
  • Over the past 5 years, InMed Pharmaceuticals' Total Current Liabilities (Quarterly) stood at $4.6 million in 2021, then slumped by 48.01% to $2.4 million in 2022, then plummeted by 30.00% to $1.7 million in 2023, then rose by 6.57% to $1.8 million in 2024, then grew by 8.29% to $1.6 million in 2025.
  • Its Total Current Liabilities was $1.6 million in Q3 2025, compared to $1.8 million in Q2 2025 and $1.8 million in Q1 2025.